Mankind Pharma Ratios

Mankind Pharma Ltd Ratios

The Mankind Pharma Ltd Ratios page provides a complete fundamental analysis of Mankind Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Mankind Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Mankind Pharma Ltd (NSE: MANKIND, BSE: 543904) is currently trading at ₹2240.10, with a market capitalization of ₹923.78B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Mankind Pharma Ltd remains a key stock for fundamental analysis using Mankind Pharma Ltd Ratios.

Mankind Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Mankind Pharma Ltd P/E ratio currently stands at 49.26, making it one of the most tracked metrics in Mankind Pharma Ltd Ratios.

Historically, the Mankind Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 49.26
• 2023: 48.18
• 2022: 0
• 2021: 0
• 2020: 0

The rising Mankind Pharma Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Mankind Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 6.98.

Historical P/B trend:

• 2024: 6.98
• 2023: 9.83
• 2022: 0
• 2021: 0

Mankind Pharma Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Mankind Pharma Ltd P/S ratio currently stands at 8.03, an important part of Mankind Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 8.03
• 2023: 8.98
• 2022: 0
• 2021: 0

A stable or declining Mankind Pharma Ltd P/S ratio indicates cautious market sentiment.

Mankind Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Mankind Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 41.12.

Historical Mankind Pharma Ltd Price to Cash Flow Ratio:

• 2024: 41.12
• 2023: 42.53
• 2022: 0
• 2021: 0
• 2020: 0

The declining Mankind Pharma Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Mankind Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Mankind Pharma Ltd EV currently stands at ₹1040B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 1040B
• 2023: 891.26B
• 2022: 0
• 2021: 0

Mankind Pharma Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Mankind Pharma Ltd EV/EBITDA ratio is currently 33.63, a key metric in Mankind Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 33.63
• 2023: 34.81
• 2022: 0
• 2021: 0

Stable Mankind Pharma Ltd EV/EBITDA indicates balanced valuation.

Mankind Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Mankind Pharma Ltd D/E ratio is currently 0.59, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.59
• 2023: 0.02
• 2022: 0.02
• 2021: 0.14

Mankind Pharma Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Mankind Pharma Ltd ROE currently stands at 16.77%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 16.77
• 2023: 22.76
• 2022: 18.86
• 2021: 26.36

Mankind Pharma Ltd maintains stable profitability levels.

Mankind Pharma Ltd Ratios Analysis Summary

The Mankind Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Mankind Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Mankind Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.